Accelr8 Posts Flat Revenues, Narrowed Loss in Fiscal Q1; Sheds No Light on BACcelr8r Availability

Dec 20, 2006

NEW YORK (GenomeWeb News) — Accelr8 Technology yesterday said fiscal first-quarter revenues were unchanged though net loss decreased 30 percent.

Total receipts for the three months ended Oct. 31 were flat at $86,000.

Accelr8 said net losses declined to $539,000 from $772,000 in the year-ago period.

The company attributed the decline to reduced research expenses for its BACcelr8r bacterial-analysis system, which is being prepared for clinical trials.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Privacy Policy Information, Please

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

Moving the Parts About

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

This Week in Science

In Science this week: genetic overlap among many psychiatric disorders, and more.

Just Skip that Step

The Economist writes that an increasing number of scientific journals don't do peer review.

Main menu